PlainPharmaWatch

CMS Open Payments · Program Year 2024

Biofrontera Bioscience GmbH

Biofrontera Bioscience GmbH reported $1,342,984.83 across General Payments, Research, and Ownership to 0 physicians and teaching hospitals across 150 transactions.

See the rankings → How this is sourced
$1.3M
All-tracks total
150
Transactions
0
Recipients
−$6.2K
General Payments vs PY2022

Biofrontera Bioscience GmbH reported $1,342,984.83 across all CMS Open Payments tracks (General + Research + Ownership) to 0 physicians and teaching hospitals in Program Year 2024 - ranking #547 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total), averaging $0.00 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer biofrontera-bioscience-gmbh Biofrontera Bioscience GmbH

$1.3M · #547/1,925 · 0.0% industry · PY2024

  • TOT $1.3M
  • RANK #547
  • SHARE 0.0%
  • TXN 150
  • RCP 0
  • CAT 0
  • GEN n/a
  • ΔGEN −$6.2K
  • PY 2024

Volume peers

Nearest volume peer: Vericel Corporation ($1.3M)

Biofrontera Bioscience GmbH …$1.3MVericel Corporation$1.3MTelix Pharmaceuticals$1.3MLeadiant Biosciences, Inc.$1.3MSurmodics, Inc.$1.3M
All-tracks payment totals near Biofrontera Bioscience GmbH (CMS Open Payments PY2024)

Biofrontera Bioscience GmbH sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2022 to PY2023

Biofrontera Bioscience GmbH's CMS-reported General Payments decreased by $6.2K (−93.3%) from PY2022 to PY2023.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BIOFRONTERA BIOSCIENCE GMBHPY2023: BIOFRONTERA BIOSCIENCE GMBHPY2024: Biofrontera Bioscience GmbH. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2022 vs PY2023

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2022$6.7KPY2023$448.00
PY2022
$6,651.00
PY2023
$448.00

What the Data Shows for Biofrontera Bioscience GmbH

Averaging $9.0K per transaction and $0.00 per recipient, Biofrontera Bioscience GmbH's Program Year 2024 total comes to $1,342,984.83 across 150 transactions and 0 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #547 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 0-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). Payments are distributed across multiple categories without a dominant single type.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Biofrontera Bioscience GmbH.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Biofrontera Bioscience GmbH's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.